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ABSTRACT 
Objective: In this study cadmium sulfide (CdS) and nickel oxide (NiO) nanoparticles were synthesized and applied as novel nanocarriers for 
antibacterial drug clarithromycin (CLA) and anticancer drug paclitaxel (PTX) to improve their physical properties and biological activities. 
Methods: Cadmium sulfide (CdS) and nickel oxide (NiO) nanoparticles were synthesized by chemical co-precipitation and thermochemical 
processing techniques respectively and loaded with clarithromycin (CLA) and paclitaxel (PTX) by simple new one-step reaction. Analytical 
measures including FTIR, PXRD, SEM, AFM, TGA, DSC and zeta potential where used for characterization. The in vitro release, antibacterial as well as 
anticancer activities were evaluated. 
Results: Analytical measures revealed that the loading involved physical complex formation rather than chemical modification with the high 
percent surface loading of the drugs on the nanoparticles. Solubility/dissolution study revealed higher significant* improvement in the solubility of 
CLA from NiO nanoparticles than that from CdS nanoparticles while the antibacterial activity of CLA was non-significantly improved. For PTX loaded 
on CdS and NiO nanoparticles showed non-significant change in its solubility, but remarkable significant* increase in its antitumor activity on MCF-7 
cell line accompanied with significant* reduction in its cytotoxicity on normal mammary cell line (MCF-10A) indicating the selectivity and targeting 
of PTX-CdS/NiO nanocarriers with reduced side effects of the drug and the used metal nanocarriers. 
Conclusion: This work provided most selective and safe delivery system for PTX and best method for enhancement of CLA solubility. 
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INTRODUCTION 
Nanocarriers are nanomaterials being used as transport modules for 
another substance such as drugs [1]. Nanocarriers with improved 
biological and physicochemical properties are taken up by cells 
more easily than larger molecules, so they can be successfully used 
as delivery tools for currently available bioactive compounds [2]. 
Among nanoparticles with biomedical advantages are inorganic 
nanoparticles which include metals (gold, copper, silver, magnesium 
and iron), metal oxides (iron oxide, zinc oxide, titanium dioxide and 
cerium oxide) and quantum dots (cadmium selenide and cadmium 
sulfide) [3]. Metal NPs are unique with various biomedical 
applications involving drug and gene delivery, highly sensitive 
diagnostic assays, radiotherapy enhancement and thermal ablation 
[4]. Nickel oxide (NiO) is an important metal oxide that has been 
applied in the medical field and as a catalyst in magnetic recording 
media as well as its cytotoxic and anticancer activity [5, 6]. 
Quantum dots (QDs) are nanocrystalline semiconductors with 
unique optical and electronic properties [7]. Cadmium sulfide (CdS) 
nanocrystals are QDs that have the advantages of high 
photostability, high quantum yield, bio-imaging of living cells and as 
a fluorescence probe for the rapid determination of DNA [8, 9]. In 
spite of its cytotoxicity, cadmium is the main component in most 
QDs which cadmium inhibit DNA, RNA and proteins synthesis, DNA 
strands breaking and chromosomes mutation [10]. In addition CdS 
nanoparticles decrease the viability of HeLa cells with increased NPs 
concentration as well as the cell division expression of E. coli was 
decreased when exposed to CdS nanoparticles [11]. 
Paclitaxel (Taxol) is a widely used chemotherapeutic drug, it is a 
FDA-approved drug for the treatment of ovarian cancers, breast, 
lungs and AIDS related Kaposi’s sarcoma [12]. Paclitaxel acts by 
promotion of microtubules stabilization and induce cytotoxic effect 
by increased reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) production [13]. Paclitaxel is BCS class IV drug with 
poor solubility and poor permeability [14], in which the high 
lipophilicity with very poor aqueous solubility of less than 
0.01 mg/ml as well as lack of ionizable functional groups are the 
major challenges in the paclitaxel dissolution and delivery [15].  
Clarithromycin (CLA) is a macrolide antibiotic that is indicated 
widely for the treatment of H. pylori mediated peptic ulcers as 
well as Upper Respiratory Tract Infections (URT) [16], it acts by 
binding to the 50S ribosomal subunit of susceptible organisms 
and thereby inhibiting protein synthesis through translocation 
of aminoacyl transfer RNA [17]. CLA have a dissolution rate-
limited absorption and low bioavailability after oral 
administration due to its low solubility in which CLA belongs to 
the class II of BCS [18]. 
This work involves the preparation and application of CdS and NiO 
nanoparticles as nanocarriers for clarithromycin and paclitaxel 
through simple one step reaction that may contribute to 
improvement in solubility, dissolution, permeability and their 
therapeutic activities as well as reducing their undesirable and 
adverse effects of the medically applied metals.  
MATERIALS AND METHODS 
Materials 
Paclitaxel and clarithromycin were provided by JIANGSU YEW 
PHARMACEUTICAL Co. Limited (China), sodium sulfide (Na2S. xH2O) 
was obtained from THOMAS BAKER Co. Limited (India), cadmium 
acetate dihydrate (CH3COO)2Cd.2H2O was obtained from Qualikems 
Fine Chem Co. Ltd. (India), nickel nitrate Ni(NO3)2.6H2O was 
obtained from Barcelona Co. Limited (Spain), ammonia solution 
NH4(OH) and acetonitrile C2H3N were obtained from Sinopharm 
Chemical Reagent Co. Limited (China), acetone C3H6O and ethanol 
C2H6O were obtained from Sigma Chemical Co. Limited (USA) and 
dimethyl sulfoxide (DMSO) was obtained from Loba Chemie Pvt. Ltd 
(India). 
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Methods 
Synthesis of cadmium sulfide (CdS) and nickel oxide (NiO) 
nanoparticles 
Cadmium Sulphide (CdS) nanoparticles were synthesized by 
chemical co-precipitation technique. This method involved drop 
wise titration (10 drops/min) of 0.1 M aqueous solution disodium 
sulfide onto 0.1 M aqueous solution cadmium acetate dihydrate with 
vigorous stirring (1500 rpm) and heating at 50 °C by a magnetic 
stirrer (Dragon Lab, USA). While dropping and stirring, the solution 
color change from yellow to orange, then red and finally return back 
to orange color. After dropping has been finished, the vigorous 
stirring (1500 rpm) is continued and temperature hold constant at 
50 °C for 4 h. Then the produced yellow-orange particles (final product) 
was filtered, washed with deionized water and desiccated within silica 
gel containing desiccator for three days and collected [19].  Nickel Oxide 
(NiO) NPs were synthesized by thermochemical processing method. 
This technique involved dropwise titration of 100 ml ammonium 
hydroxide solution (10 drops/min) onto preheated 0.5 M nickel 
nitrate aqueous solution to 70 °C with vigorous stirring (1500 rpm). 
As dropping has been completed, the vigorous stirring is continued, 
and the temperature kept at 70 °C for 4 h and then filtered. The 
obtained light green residue was then washed with 1:1 (v/v) ethanol 
and deionized water and heated in an oven (Memmert, Germany) to 
70 °C for 24 h followed by 220 °C for 2 h resulting in black 
nanoparticles of NiO [20, 21]. 
Loading of clarithromycin and paclitaxel on CdS nanoparticles 
Clarithromycin and Paclitaxel each one separately was loaded to CdS 
nanoparticles by incorporation method which involves the addition 
of the drug in the last step of nanoparticles synthesis, where 0.1 M of 
clarithromycin using acetone as a solvent and 0.1 M of paclitaxel 
using acetonitrile as a solvent was added (each one separately) by 
fast dropping to the mixture of cadmium acetate and sodium sulfide 
while it is vigorously stirred (1500 rpm) at 50 °C and just before 
dropping of sodium sulfide has been finished. After finishing the 
sodium sulfide dropping, the stirring was continued for 4 h and then 
filtered, washed with ethanol, desiccated and finally collected as a 
light yellow powder to be characterized and evaluated [22]. 
Loading of clarithromycin and paclitaxel on NiO nanoparticles 
Loading of clarithromycin and Paclitaxel each one separately on NiO 
nanoparticles was done by (Adsorption/Absorption) method that 
involves addition of 0.1 M of each drug by fast dropping to the 
preheated solution of NH4OH containing NiO nanoparticles at 60 °C 
with vigorous stirring (1500 rpm) that continued for 2 h after drug 
addiction had been completed. Then the mixture is filtered, washed 
with ethanol to remove impurities, desiccated and finally collected 
as a grey powder to be characterized and evaluated [23]. 
Characterization of clarithromycin and paclitaxel-loaded CdS 
and NiO nanoparticles 
Fourier Transform Infra-red spectroscopy (FTIR) 
Fourier Transform Infra-Red spectroscopy (FTIR) instrument 
(Shimadzu Japan) was used to determine the nature of associated 
functional groups, and it was employed for pure clarithromycin, 
pure paclitaxel, CdS nanoparticles loaded clarithromycin, CdS 
nanoparticles loaded paclitaxel, NiO nanoparticles loaded 
clarithromycin and NiO nanoparticles loaded Paclitaxel by FTIR 
spectroscopy (4000-500 cm-1) using potassium bromide disc [24].  
Powder X-ray diffraction (PXRD) 
PXRD was achieved for pure drugs, nanoparticles alone and 
nanoparticles loaded drugs to determine their crystallinity, in which 
the PXRD instrument (Shimadzu, Japan) was equipped with Cu-Ka 
radiation (λ = 1.54060 Ǻ), voltage (40 Kv) and current (30 mA). The 
samples were analyzed in scanning speed of (5 °/min) and axis θ-2θ 
with a range of 5 to 60 degrees [25]. 
Scanning electron microscope (SEM)  
Scanning electron microscope instrument (FET company, 
Netherlands) is used to determine the shape, size and morphologies 
of formed nanoparticle to give high-resolution images of the sample 
surface by magnifying images up to 200,000 times [26]. Sample (1-2 
mg) of produced nanoparticles before and after loading with drugs as 
well as for pure drugs was mounted on the small aluminum holder and 
coated with gold, then introduced into SEM instrument and scanned 
with a fine focused beam of electrons to take images [27]. 
Zeta potential 
Zeta (ξ) potential analysis was applied for CdS and NiO 
nanoparticles before and after loading with clarithromycin and 
paclitaxel as well as for free drugs as an indicator of their stability 
in suspension and was performed by dissolving 2 mg of each 
sample separately in 10 ml of phosphate buffer PH 7.4 with 
sonication, then filtered with 0.2 µl filter syringe and finally 
introduced to the zeta potential analyzer (Brookhaven, USA) to 
read the zeta potential data for each sample [28]. 
Thermal gravimetric analysis (TGA) 
Powder samples of pure drug, CdS and NiO nanoparticles and 
nanoparticles loaded drugs were analyzed by TGA to evaluate their 
thermal behavior during heating process (25-600 °C), in which 20 
mg of each sample was located separately in TG instrument (Linseis, 
Germany) pan so that record the weight loss with increase 
temperature by subjecting them to a constant heating rate of 5 
°C/min and nitrogen atmosphere with a gas flow of 50 ml/min. As a 
result, the thermal scan was recorded as plot of heat flow versus 
temperature [29, 30]. 
Differential scanning calorimetric (DSC) 
Differential scanning calorimetric analysis (Linseis, Germany) was 
carried out for pure drugs, CdS and NiO nanoparticles and 
nanoparticles loaded drugs by taking 10 mg of each sample and 
dispersed in 5 ml of phosphate buffer PH 7.4, then take 1 ml of the 
dispersed sample and heated from 25 °C to 300 °C at the rate of 10 
°C/min and under a carrier of nitrogen gas supplied at 10  mL/min [31]. 
Atomic force microscopy (AFM) 
Atomic Force Microscopy (Augestrom advance Inc., USA) was used 
to determine the shape, size and size distribution of nanoparticles by 
resolving individual particles and groups of particles in three 
dimensions analysis [32] and it was performed for pure drugs, CdS 
and NiO nanoparticles and nanoparticles loaded drugs. Powder 
samples were dissolved in methanol, and few drops of each sample 
were dropped separately on a silica glass plate and allowed to dry at 
room temperature to be deposited on the plate. The deposited film was 
then scanned with the Atomic Force Microscopy instrument [33]. 
Calculations of drug yield, drug entrapment efficiency, and drug 
loading percentages 
The percentage of yield was calculated as a percentage ratio of the 
weight of nanoparticles (or materials forming it) after incorporation 
of the drug with nanoparticles to the weight of nanoparticles and 
drug fed initially in the reaction before incorporation and as follows:  
% yield = 
weight of nanoparticles after drug incorporation(actual)
weight of nanoparticles and drug before incorporation(theoretical)
× 100% 
The percentage of entrapment efficiency (% e. e) of the drug was 
calculated as a percentage ratio of the weight of drug in 
nanoparticles after incorporation to the weight of drug fed initially 
in the reaction before incorporation and as follows:  
%e. e = 
weight of drug in nanoparticles after incorporation(actual) 
weight of drug fed initially before incorporation(theoretical)
× 100% 
The percentage of drug loading was calculated as a percentage ratio 
of the weight of drug in nanoparticles alone to the weight of 
nanoparticles loaded with the drug and as follow [34, 35]: 
% drug loading =
weight of drug in nanoparticles
weight of nanoparticles loaded with the drug × 100% 
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In vitro drugs release study 
Clarithromycin in vitro release study from the prepared 
nanocarriers was achieved using USP type II rotating paddle 
apparatus (Copley, UK) at ( 37+0.5 °C ) and the rotating speed of 50 
rpm in 500 ml of phosphate buffer solution (pH 7.4). Equivalent to 
100 mg CLA of the prepared CdS and NiO nanoparticles loaded with 
CLA as well as 100 mg of standard CLA were dispersed in the 
dissolution medium, and samples of 5 ml were withdrawn at 
predetermined time intervals and replaced with the same volume of 
fresh media after each withdrawal, then the withdrawn samples 
were filtered and the content of CLA was determined 
spectrophotometrically by using UV-Visible spectrophotometer 
(Shimadzu, Japan) at 210 nm, each experiment was analyzed in 
triplicate [36, 37]. 
The same was applied to paclitaxel by dispersing 10 mg of the 
standard PTX as well as equivalent to 10 mg PTX of the prepared 
CdS and NiO nanoparticles loaded with PTX in 500 ml of phosphate 
buffer solution PH 7.4 using USP type II rotating paddle apparatus 
(Copley, UK) at ( 37+0.5 °C ) and rotating speed of 50 rpm. The 
withdrawn samples were determined spectrophotometrically by 
using UV-Visible spectrophotometer (Shimadzu, Japan) at 230 nm; 
each sample was analyzed in triplicate [38].  
Solubility determination of drugs before (free drug) and after 
loading with nanoparticles 
A widely spread method to determine the equilibrium solubility of 
drug molecules is saturation shake-flask method. An excess amount 
of CLA (10 mg/ml), PTX (0.1 mg/ml) and an equivalent amount of 
each drug loaded CdS and NiO nanoparticles were dispersed 
separately in phosphate buffer PH 7.4 containing stoppered flask in 
a water bath at 37 °C and stirred by magnetic stirrer (Dragon Lab, 
USA) for 48 h. After 48 h the undissolved material was filtered, and 
the concentration of dissolved drug was quantified using UV-Visible 
spectrophotometer (Shimadzu, Japan) at the specified λ max of each 
drug in triplicate [39]. 
Antibacterial activity test of clarithromycin loaded 
nanoparticles 
The antibacterial biological activity of clarithromycin loaded CdS and 
NiO nanoparticles each separately was compared with free CLA as well 
as with blank CdS and NiO nanoparticles. Each sample was tested against 
two types of Gram+ve bacteria (Staphylococcus aureus and Streptococcus 
pyogen) and two types of Gram–ve bacteria (Serratia marcescens and 
Klebsiella oxytoca) at concentration 100 µg/ml of free CLA and an 
equivalent concentration of CLA loaded with CdS and NiO nanoparticles 
as well as blank CdS and NiO nanoparticles. The samples were dissolved 
using dimethyl sulfoxide (DMSO) as a solvent and cultured in Muller 
Hinton agar for 24 h at 37 °C [40, 41].  
Antitumor activity of paclitaxel-loaded nanoparticles 
The antitumor activity of paclitaxel before and after loading with 
CdS and NiO nanocarriers as well as of blank CdS and NiO 
nanoparticles was performed by Centre for Natural Products 
Research and Drug Discovery in the University of Malaya using the 
following procedures:  
Cell culture 
The human cancer breast cell line (MCF-7) and human mammary 
epithelial cell line (MCF-10A) were grown each separately in 
Dulbecco modified Eagle’s medium (DMEM) with 10% (v/v) heat-
inactivated newborn calf serum and antibiotics (100 mg/ml of 
streptomycin and 100 U/ml of penicillin) at 37 °C in a humidified 
atmosphere containing 5% CO2 [42]. 
MTT assay 
MCF-7 cells and MCF-10A cells were seeded separately in a 96-well 
plate (0.8×104 cells/well) in triplicate and incubated for 24 h to be 
attached to the plates. After incubation for 24 h, cells were treated 
with increasing concentrations (2.5, 5, 10, 20 nM) of pure paclitaxel, 
paclitaxel loaded CdS and NiO nanoparticles and blank CdS and NiO 
nanoparticles for 24, 48 and 72 h respectively [43, 44]. After 
respective incubation periods, 20 µl (5 mg/ml) of MTT (3-(4,5 
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) was added 
to each well and incubated for 4 h at 37 °C. Then the formazan 
crystals formed by the viable cells were dissolved by the addition of 
200 µl of DMSO to each well, and the color intensity value of the 
processed cells was measured at 550 nm that presents the cell 
survival percentage in corresponding wells in contrast with their 
respective controls [42, 45]. 
Statistical analysis 
All the experiments were conducted in triplicates, and the 
comparisons of quantitative data obtained from antibacterial and 
antitumor activity of clarithromycin and paclitaxel respectively were 
analyzed using one-way, and two-way ANOVA tests, as well as 
Student T-test, was used for clarithromycin quantitative data 
comparison for in vitro release, the results were expressed as 
mean±standard deviation. Statistical analysis was performed using 
the statistical package SPSS for windows (version 13, SPSS Inc., 
Chicago, IL, USA). The statistical significance for each test a P value 
of less than 0.05 was adopted. 
RESULTS 
Synthesis of cadmium sulfide (CdS) and nickel oxide (NiO) 
nanoparticles 
The reaction of 0.1 M of sodium sulfide Na2S with 0.1 M of cadmium 
acetate (CH3COO)2Cd in special conditions resulted in an orange 
precipitated nanoparticles of cadmium sulfide (CdS) according to the 
following equation [46]: 
Na2S+Cd (CH3COO)2 → CdS (NPs)↓+ ( 2CH3COONa ) .The reaction of 
0.5 M of Nickel nitrate Ni(NO3)2.6H2O with ammonium hydroxide 
NH4OH with vigorous stirring (1500 rpm) and heating (70 °C) for 4 
h, followed by heating in the oven for 24 h with 70 °C, after that rise 
the temperature in the oven up to 220 °C for 2 h to calcify the 
product resulted in black precipitate of nickel oxide nanoparticles as 
displayed in following equation [47]: 
Ni(NO3)2+2NH4OH → NiO (NPs)↓+2NH4NO3+H2O 
Loading of the drugs on CdS and NiO nanoparticles 
The drugs are believed to be loaded on cadmium sulfide (CdS) 
nanoparticles by physical complexation without any chemical reaction, 
in which a yellow powder was obtained for both CLA and PTX loaded 
CdS nanoparticles as a new compound that differ from the original 
color of CLA (white) and PTX (white) as well as from the original color 
of CdS nanoparticles (orange) resulting from complex formation 
between the drugs and the nanocarrier. The loading of clarithromycin 
and paclitaxel on nickel oxide (NiO) nanoparticles (black 
nanoparticles) was obtained as a grey powder resulting from the 
complexation of the drugs with nanoparticles by physical attraction.  
Characterization of clarithromycin and paclitaxel-loaded CdS 
and NiO nanoparticles 
Furrier transform infra-red (FTR) 
The FTIR spectrum (fig. 1) of clarithromycin displays bands at the 
range (3618–3420 cm-1) attributed to multiple hydroxyl groups 
(OH) in the backbone structure of CLA. The bands at 1722 cm-1and 
1697 cm-1assign to the two carbonyl groups of ester and ketone 
respectively, while the aliphatic groups (CH3 and CH2) were 
appeared in the expected area for the stretching (asymmetrical and 
symmetrical) in the range (1990-2781 cm-1) while the finger prints 
area shows the bending bands of the drug. The FTIR spectrum of 
CLA loaded CdS nanoparticles, and CLA loaded NiO nanoparticles 
shows the OH and other groups appeared in the same values with 
that of free CLA with small shifting. The FTIR spectrum of paclitaxel 
shows peaks at 3510 cm-1 and 3439 cm-1can be attributed to 
stretching of a hydroxyl group (OH) in two different environments; 
the amidic group was shown at 3350 cm-1. The bands at 3063 cm-1 
and 3021 cm-1 assign to aromatic CH stretching, while the carbonyl 
groups appear as multiband due to the different environments of 
these groups at 1712, 1700, 1647 and 1602 cm-1. The FTIR spectrum 
of loaded drug (PTX) with CdS and NiO nanoparticles appeared with 
the same functional groups of free PTX with small shifting. 
Maraie et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 5, 322-333 
325 






Fig. 1: FTIR of (A) pure clarithromycin, (B) pure paclitaxel, (C) CLA loaded CdS nanoparticles, (D) PTX loaded CdS nanoparticles, (E) CLA 
loaded NiO nanoparticles and (F) PTX loaded NiO nanoparticles. CLA: clarithromycin; PTX: paclitaxel; CdS: cadmium sulfide; NiO: nickel 
oxide 
 
X-Ray diffraction (XRD) 
The X-Ray Diffraction (XRD) spectrum (fig. 2) of blank CdS and NiO 
nanoparticles displays sharp, intense peaks with high multiplicity 
indicating crystalline property. The XRD spectrum of free 
clarithromycin displays numerous narrow strongly intense 
diffraction peaks indicating its highly stable crystalline structure, 
while the XRD of CLA loaded on CdS and NiO nanoparticles show 
less intense and less characterized sharp diffraction peaks with 
decreased multiplicity in comparison with the XRD of free CLA 
referring to the more amorphous compound. The XRD spectrum of 
free paclitaxel displays many characterized narrow sharp diffraction 
peaks indicating PTX crystalline structure, while the XRD spectrum 
after loading of PTX on CdS and NiO nanoparticles displays 
increased multiplicity of sharp diffraction peaks with higher 
intensities in general except some characteristic peak of free PTX 
referring to enhanced crystalline property of PTX loaded 










Fig. 2: XRD of (A) blank CdS nanoparticles, (B) blank NiO nanoparticles, (C) pure clarithromycin, (D) pure paclitaxel, (E) CLA loaded CdS 
nanoparticles, (F) PTX loaded CdS nanoparticles, (G) CLA loaded NiO nanoparticles and (H) PTX loaded NiO nanoparticles 
CLA: clarithromycin; PTX: paclitaxel; CdS: cadmium sulfide; NiO: nickel oxide 
 
Scanning electron microscopy (SEM) 
The scanned electronic microscope (SEM) images (fig. 3) of 
loaded clarithromycin with CdS and NiO nanoparticles display 
different shape and size in comparison with the free CLA and 
blank CdS and NiO nanoparticles, in which these complexes of 
loaded drug appeared more distributed as well as more compact 
with smoother surfaces. The same changes were observed with 
the SEM images of paclitaxel after loading with CdS and NiO 
nanoparticles as they appeared more compact with smoothly 
fine surfaces than that of free PTX with flakes like shape for PTX-
NiO complex. 
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Fig. 3: SEM of (A) blank CdS nanoparticles, (B) blank NiO nanoparticles, (C) pure clarithromycin, (D) pure paclitaxel, (E) CLA loaded CdS 
nanoparticles, (F) PTX loaded CdS nanoparticles, (G) CLA loaded NiO nanoparticles and (H) PTX loaded NiO nanoparticles. CLA: 
clarithromycin; PTX: paclitaxel; CdS: cadmium sulfide; NiO: nickel oxide 
Table 1: Zeta potential of CdS and NiO nanoparticles before and after loading with clarithromycin and paclitaxel as well as pure drugs 








Cds nanoparticles -152.45±4.8 -3.03±0.10 223.44±0.62 -27.04±0.95 
NiO nanoparticles -90.82±4.1 -1.80±0.08 235.03±0.64 -16.84±1.71 
Pure clarithromycin -119.67±8.23 -2.38±0.16 230.45±1.26 -19.25±4.51 
Clarithromycin loaded  
CdS nanoparticles 
-32.54±2.1 -2.15±0.16 232.04±1.48 -16.70±2.81 
Clarithromycin loaded  
NiO nanoparticles 
-59.58±6.94 -1.18±0.14 240.65±1.10 -7.68±1.83 
Pure paclitaxel -77.76±4.08 -1.54±0.08 237.13±0.67 -13.98±1.57 
Paclitaxel loaded CdS nanoparticles -117.90±8.95 -2.34±0.18 231.57±1.44 -18.84±1.69 
Paclitaxel loaded NiO nanoparticles -72.93±2.85 -1.45±0.06 238.44±0.46 -11.78±1.65 
Data represent mean(±SD ) (n=3). CdS: cadmium sulfide; NiO: nickel oxide. 
 
 Zeta potential  
The zeta potential values are summarized in (table 1) and indicate 
good stability of clarithromycin loaded CdS and NiO nanoparticles 
(below-30 mV). The zeta potential of paclitaxel is loaded CdS and 
NiO nanoparticles display excellent stability (below-60 mV) against 
aggregation [48]. 
Thermogravimetric analysis (TGA) 
Thermo Gravimetric Analysis (TGA) spectrum (fig. 4) of the 
prepared blank CdS nanoparticles shows a peak at 398.8 °C 
indicating its degradation after this temperature while the TGA of 
blank NiO nanoparticles shows its degradation peak at 399 °C. 
Thermal analysis of free clarithromycin shows a peak at 279 °C that 
is corresponding with the melting of CLA and decomposition of the 
compound after this degree. Thermal analysis of CLA loaded CdS 
nanoparticles shows peak at 255.5 °C referring to initiation of 
decomposition (weight loss) of the CLA-CdS complex followed by 
degradation above this degree, while CLA loaded NiO nanoparticles 
thermal analysis shows thermal peak at 276 °C indicating loss of 
drug by melting since it is close to the melting of free CLA and 
followed by its decomposition above this temperature. Thermal 
analysis of paclitaxel shows sharp thermal peak at 230.9 °C that is 
related to the PTX melting since the drug decompose above this 
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temperature, while thermal analysis of PTX loaded CdS 
nanoparticles shows broad weight loss thermal peak at 213.8 °C that 
result from partial drug decomposition at this peak followed by 
stationary thermal stability without degradation of PTX-CdS 
complex, while the paclitaxel loaded NiO thermal analysis displays 
two steps of weight loss by thermal effect, first thermal peak 
appears at 229.6 °C indicating the melting of PTX since it is close to 
the melting of free drug and followed by decomposition of PTX, 
while the second thermal peak appears at 359.8 °C that results from 










Fig. 4: TGA of (A) blank CdS nanoparticles, (B) blank NiO nanoparticles, (C) pure clarithromycin, (D) pure paclitaxel, (E) CLA loaded CdS 
nanoparticles, (F) PTX loaded CdS nanoparticles, (G) CLA loaded NiO nanoparticles and (H) PTX loaded NiO nanoparticles. CLA: 
clarithromycin; PTX: paclitaxel; CdS: cadmium sulfide; NiO: nickel oxide 
 
Differential scanning calorimetric (DSC) 
The Differential Scanning Calorimetric (DSC) spectrum (fig. 5) of blank 
CdS and NiO nanoparticles display no sharp endothermic peak, while 
the DSC spectrum of free CLA displays a sharp narrow, intense 
endothermic peak at 228.58 °C that corresponds to the melting of the 
drug indicating its crystallinity [49] and decomposition of the drug 
after this temperature. The DSC spectrum of loaded CLA with CdS 
nanoparticles shows a small non-intense peak at 92.1 °C that indicates 
the initiation of melting of the complex and sharp, intense 
endothermic peak at 223.07 °C referring to melting of CLA followed by 
degradation of the compound. While the DSC spectrum of CLA-NiO 
complex displays sharp endothermic peak at 228.1 °C that indicates 
melting and finally degradation of the compound. The DSC spectrum of 
free paclitaxel shows sharp narrow endothermic peak at 217.65 °C 
that is attributed to the melting of the drug indicating its crystallinity 
[50], while the DSC spectrum obtained with PTX-CdS complex shows 
wide broad non-sharp endothermic peak at 109 °C that indicate the 
initiation of melting and another broad small endothermic peak at 
165.04 °C corresponding to further melting and degradation of the 
new crystalline compound. The PTX-NiO complex shows DSC 
spectrum with multiple endothermic peak that appears as broad wide 
small peak at 163.8 °C that indicates the initiation of melting. 
Additionally, small intense peaks also appeared at 219.4, 245.54 and 
256.68 °C indicating a shifting of free PTX melting peak and crystalline 
nature of new compound due to multiple endothermic peaks. 
Atomic force microscopy (AFM) 
The Atomic Force Microscopy (AFM) showed fine particle size 
distribution (fig. 6) of particles for clarithromycin loaded CdS and 
NiO nanoparticles with smooth surfaces as shown in AFM images 
(fig. 7) in comparison with free CLA and blank CdS and NiO 
nanoparticles. The same was observed in paclitaxel, in which AFM 
images of loaded PTX with CdS and NiO nanoparticles show rice shaped 
particles with smooth surfaces and fine distribution than that of free 
PTX. The average particle size was also determined by AFM 
measurement, in which the average sizes of CLA loaded CdS and NiO 
nanoparticles were 125.51 and 98.85 nm respectively, that were higher 
than that of free CLA (74.99 nm), blank CdS nanoparticles (83.18 nm) 
and blank NiO nanoparticles (82.57 nm). The same was observed for 
paclitaxel, in which the average size of PTX before loading was 95.28 nm 
while the average sizes after loading with CdS and NiO nanoparticles 
were 116.7 nm and 106.03 nm respectively indicating drug loading of 
CLA and PTX with the CdS and NiO nanoparticles. 
Yield, entrapment efficiency and drug loading percentages 
The yield percentage of the reaction involving clarithromycin with 
CdS and NiO nanoparticles after complexation was 66.34% and 
64.1% respectively. While the yield percentage of the reaction 
involving with paclitaxel-loaded CdS and NiO nanoparticles was 
62.9% and 95.04% respectively. The drug content of clarithromycin 
and paclitaxel that has been loaded on CdS and NiO nanocarriers 
was expressed as percentage of drug loading, in which for CLA 
loaded CdS and NiO nanoparticles was 56.66% and 86.6% 
respectively and for PTX loaded CdS and NiO nanoparticles was 
76.65% and 95.67% respectively. The percentage of clarithromycin 
that has been efficiently entrapped with CdS and NiO nanoparticles 
was 92.67% and 94.6% respectively while the percentage of 
entrapment efficiency for paclitaxel with CdS and NiO nanoparticles 
was 123.66% and 104% respectively. 
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Fig. 5: DSC of (A) blank CdS nanoparticles, (B) blank NiO nanoparticles, (C) pure clarithromycin, (D) pure paclitaxel, (E) CLA loaded CdS 
nanoparticles, (F) PTX loaded CdS nanoparticles, (G) CLA loaded NiO nanoparticles and (H) PTX loaded NiO nanoparticles. CLA: 










Fig. 6: AFM particle size distribution of (A) blank CdS nanoparticles, (B) blank NiO nanoparticles, (C) pure CLA, (D) pure PTX, (E) CLA 
loaded CdS nanoparticles, (F) PTX loaded CdS nanoparticles, (G) CLA loaded NiO nanoparticles and (H) PTX loaded NiO nanoparticles. 
CLA: clarithromycin; PTX: paclitaxel; CdS: cadmium sulfide; NiO: nickel oxide 
Maraie et al. 










Fig. 7: AFM two and three dimensional images of (A) blank CdS nanoparticles, (B) blank NiO nanoparticles, (C) pure clarithromycin, (D) 
pure paclitaxel, (E) CLA loaded CdS nanoparticles, (F) PTX loaded CdS nanoparticles, (G) CLA loaded NiO nanoparticles and (H) PTX 
loaded NiO nanoparticles. CLA: clarithromycin; PTX: paclitaxel; CdS: cadmium sulfide; NiO: nickel oxide 
 
Solubility determination of drugs before (free drug) and after 
loading with nanoparticles 
The results are illustrated in (table 2) indicating that the solubility of 
clarithromycin loaded on CdS and NiO nanocarriers was significantly* 
improved in comparison with the saturated solubility of free CLA, while 
paclitaxel shows the non-significant difference in the saturated solubility 
after loading on CdS and NiO nanoparticles from that of unloaded PTX. 
In vitro drugs release study 
The in vitro release of clarithromycin (fig. 8) from drug loaded 
nanoparticles in comparison to pure CLA shows that the percentage 
release of CLA after 30 min equal 34.1% from pure CLA, while the 
release after 30 min was found to be 49.86% and 88.95% from CLA-
CdS and CLA-NiO complexes respectively. The release percentage of 
CLA reaches 100% from CdS and NiO nanoparticles within 150 and 
45 min respectively, while pure CLA gave only 57% release within 
150 min indicating significantly* faster dissolution and release of 
drug from CLA-NiO complex than that of CLA-CdS complex and both 
of them shows higher dissolution than pure drug.  
No release profile was detected for paclitaxel from CdS and NiO 
nanocarriers as well as for pure PTX after 8 h due to very low 
solubility of the drug. 
  
Table 2: Saturated solubility of clarithromycin and paclitaxel before and after loading with CdS and NiO nanoparticles 
Sample Solubility  (mg/ml) 
Clarithromycin  0.203±0.017 
Clarithromycin loaded CdS nanoparticles 0.397±0.035 
Clarithromycin loaded NiO nanoparticles 0.510±0.048 
Paclitaxel  0.0145±0.0012 
Paclitaxel loaded CdS nanoparticles 0.0127±0.0011 
Paclitaxel loaded NiO nanoparticles 0.0112±0.0012  
Saturated solubility data represent mean( ±SD ) (n=3). CdS: cadmium sulfide; NiO: nickel oxide 
 
Antibacterial activity test of clarithromycin loaded 
nanoparticles  
The antibacterial activity of clarithromycin loaded CdS and NiO 
nanoparticles in comparison with free CLA and blank nanoparticles 
(CdS and NiO) was determined by measuring the zone of inhibition 
(ZOI) caused by each sample separately in Muller Hinton agar at 37 
°C and 24 h incubation. The results illustrated in (table 3) where 
there was the non-significant difference in the activity of CLA before 
and after loading with CdS and NiO nanoparticles on Gram+ve 
bacteria Staphylococcus aurous and Streptococcus pyogen and on 
Gram–ve bacteria Serratia marcescens, while there is no effect on 
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Gram-ve bacteria Klebsiella oxytoca. Blank CdS nanoparticles 
showed no activity against all examined bacteria while NiO 
nanoparticles showed antibacterial activity only against Gram+ve 
bacteria. The solvent used (DMSO) showed no effect in all samples. 
 
 
Fig. 8: Comparative in vitro release profile of pure clarithromycin, CLA loaded CdS nanoparticles and CLA loaded NiO nanoparticles in 
phosphate buffer solution (pH 7.4). Cumulative drug release percent data points represent mean(±SD) (n=3). CLA: clarithromycin; CdS: 
cadmium sulfide; NiO: nickel oxide 
 
Table 3: Antibacterial activity of pure clarithromycin, clarithromycin loaded CdS and NiO nanoparticles and blank CdS and NiO 
nanoparticles represented by zone of inhibition (mm) 




 Control (dimethyl sulfoxide) _ _ _ _ 
Pure clarithromycin 31±2.5  32±2.6 20±1.8 _ 
Clarithromycin loaded  
CdS nanoparticles 
32±3 34±3.1 20±1.5 _ 
Clarithromycin loaded  
NiO nanoparticles 
32±2.8 35±3.3 22±2 _ 
CdS nanoparticles _ _ _ _ 
NiO nanoparticles 20±1.7 16±1.2 _ _ 






Fig. 9: Comparative in vitro cytotoxicity of pure paclitaxel, PTX loaded CdS nanoparticles, PTX loaded NiO nanoparticles, blank CdS 
nanoparticles and blank NiO nanoparticles showing the effect of concentration on their anticancer activity on MCF-7 cell line after (A) 24, 
(B) 48 and(C)72 h of exposure, (D) Time-response curve for PTX using 2.5 nM concentration. Inhibition rate percent data points 
represent mean(±SD) (n=3). PTX: paclitaxel; CdS: cadmium sulfide; NiO: nickel oxide 
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Cytotoxic activity of paclitaxel-loaded nanoparticles 
MCF-7 and MCF-10A cells were treated with increasing 
concentrations of paclitaxel before and after loading with CdS and 
NiO nanoparticles as well as with blank CdS and NiO nanoparticles 
where each sample was dissolved in dimethyl sulfoxide (DMSO), 
knowing that DMSO showed no or negligible cytotoxic activity 
(inhibition rate percent IR %) on both tumor and normal cells.   
Paclitaxel from PTX loaded CdS and NiO nanocarriers shows 
significantly* higher cytotoxic effect (high IR %) than that of pure 
PTX and blank CdS and NiO nanoparticles on MCF-7 cancer cell line 
(fig. 9) in all concentrations used (2.5-20 nM) at different times of 
exposure (24, 48 and 72 h). The IR % for all concentrations of the 
same sample was almost the same indicating dose-independent 
kinetic. In addition, there was the non-significant difference in the IR 
% between PTX loaded on CdS and on NiO nanoparticles. To 
evaluate the cytotoxic effect of paclitaxel loaded CdS and NiO 
nanoparticles on MCF-10A human mammary epithelial cell line (fig. 
10) the same concentrations and times of exposure were applied. It 
was found that the undesirable cytotoxic effect of PTX loaded CdS 
and NiO nanoparticles on MCF-10A (normal human mammary 
epithelial cell line) were significant* lower than that of pure PTX and 
blank CdS and NiO nanoparticles from all used concentrations and at 
different times of exposure. Upon comparison with its cytotoxic 
activity on cancer cells, variable dose-kinetic was observed where 
above 2.5 nM variable changes observed including steep decline 
observed after 48 h, while after 72 h the steep decline was observed 






Fig. 10: Comparative in vitro cytotoxicity of pure paclitaxel, PTX loaded CdS nanoparticles, PTX loaded NiO nanoparticles, blank CdS 
nanoparticles and blank NiO nanoparticles showing the effect of concentration on their anticancer activity on MCF-10A cell line after (A) 
24, (B) 48 and (C)72 h of exposure, (D) Time-response curve for PTX using 2.5 nM concentration. Inhibition rate percent data points 
represent mean(±SD ) (n=3). PTX: paclitaxel, CdS: cadmium sulfide, NiO: nickel oxide 
 
DISCUSSION 
The synthesis of clarithromycin/paclitaxel–CdS/NiO complexes was 
carried out using one-step reaction with high yield % indicating its 
simplicity and applicability. The loading of CLA and PTX on CdS and 
NiO nanoparticles was evaluated depending on changes in 
crystallinity, solubility, dissolution, particle size, morphology as well 
as their biological activities. The IR spectra (fig. 1) shows the same 
main functional groups of CLA and PTX before and after loading with 
CdS and NiO nanoparticles with small shifting, indicating physical 
complexes formation between each drug and nanocarriers rather 
than chemical interaction [36, 51, 52]. 
The smooth surfaces and fine distribution of drug-nanocarrier 
complexes than that of free CLA, free PTX and blank CdS and NiO 
nanoparticles showed by SEM and AFM (fig. 3, 6 and 7) indicate 
surface loading of drugs [52, 53] that accommodate also with the 
results obtained from TGA spectra (fig. 4), where TGA spectra of CLA 
after loading with CdS and NiO nanoparticles showed thermal 
weight loss peaks at 255.5 °C and 276 °C respectively that is close to 
the melting peak of free CLA at 279 °C, while TGA spectra of PTX 
loaded CdS and NiO nanoparticles showed thermal weight loss peaks 
at 213.8 °C and 229.6 °C respectively that is also close to the melting 
peak of unloaded PTX at 230.9 °C [54, 55]. Additionally, the high % 
yield, % drug loading and % entrapment efficiency indicate high 
drug loading with the surface complex formation. Particle size 
increment that was detected by SEM and AFM measurements after 
loading of CLA and PTX on CdS and NiO nanoparticles in comparison 
with that of free drugs and blank nanoparticles (CdS and NiO) also 
confirm their loading [53, 56, 57].  
The in vitro release of CLA from nanocarriers (fig. 8) was 
significantly* increased in comparison with free CLA, this increased 
dissolution and solubility could be caused by the phase transition 
from crystalline to amorphous structure that was approved with 
XRD and DSC spectra (fig. 2 and 5 respectively), where the XRD 
spectra of CLA after loading with CdS and NiO nanoparticles showed 
less characterized as well as less intense sharp peaks with decreased 
multiplicity in comparison with unloaded CLA indicating enhanced 
amorphous property [58], while the DSC spectra of CLA loaded CdS 
and NiO nanoparticles showed shorter crystalline endothermic 
peaks at 223.07 °C and 228.1 °C respectively than that of unloaded 
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CLA which showed longer more crystalline endothermic peak at 
228.58 °C [41, 49, 59]. For PTX; the non-significant difference in its 
saturated solubility for pure PTX and loaded complexes, in addition 
to the undetectable release profile indicating the formation of more 
crystalline complexes that was also approved by XRD and DSC 
spectra (fig. 2 and 5 respectively), where the XRD spectrum of 
loaded drug showed enhanced multiplicity of diffraction peaks for 
both CdS and NiO complexes indicating more crystalline compounds 
obtained, while the DSC spectra of PTX loaded CdS (endothermic 
peaks at 109 °C and 165.04 °C) and NiO (endothermic peaks at 
163.8, 219.4, 245.54 and 256.68 °C) nanoparticles showed more 
than one endothermic peak indicating more than one glass 
transition temperature and more crystallinity [57, 60, 61]. These 
results are indicating that the loading of PTX on CdS and NiO 
nanoparticles did not improve its solubility/dissolution profile. 
To evaluate the effect of drug loading on CdS and NiO nanoparticles on 
the biological activity, the antibacterial activity of CLA loaded on CdS and 
NiO nanoparticles (table 3) showed non-significant improvement in 
comparison to the unloaded drug, although the loading process 
significantly* improve the solubility/dissolution profile of the drug. 
The anticancer activity of PTX (fig. 9) against breast cancer cells 
(MCF-7) was significantly* improved upon loading on CdS and NiO 
nanoparticles in comparison with the free drug, although the metal 
nanoparticles showed limited anticancer activity indicating that the 
loading process led to improve the permeability of the drug through 
the tumor cells by providing more stable PTX loaded complexes [43, 
60, 62] and/or due to sustained release manner of PTX from 
nanocarriers [63] in addition to the synergistic effect of CdS (,) NiO 
nanoparticles [64]. While the undesirable cytotoxic effect of loaded 
drug (fig. 10) on normal mammary epithelial cells (MCF-10A) was 
significantly* lower than that of pure PTX and CdS and NiO 
nanoparticles, this could be attributed to the increased resistance of 
normal cells toward PTX loaded on CdS and NiO nanoparticles.  
CONCLUSION 
This work presents simple one-step reaction for loading of CLA and 
PTX using CdS and NiO nanoparticles with high % yield and loading 
content that improve the solubility/dissolution profile of CLA 
significantly* with non-significant improvement of its antibacterial 
activity, while for PTX, a remarkable significant* improvement in its 
anticancer activity was obtained after loading with CdS and  NiO 
nanoparticles, in addition to significant* reduction in its cytotoxic 
effect on normal cells indicating an improvement in targeting and 
selectivity of the drug which is very well known to have a wide range 
of side effects through improving its permeability into the cancer 
cells rather than normal cells, although non-significant improvement 
in solubility/dissolution profile was observed.  
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